Publicacions en col·laboració amb investigadors/ores de Hospital Universitario La Fe (22)

2019

  1. Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation

    Annals of Hematology, Vol. 98, Núm. 9, pp. 2151-2162

2015

  1. Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: Results from the Spanish registry

    Leukemia, Vol. 29, Núm. 9, pp. 1875-1881

  2. Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: A population-based study

    The Lancet Haematology, Vol. 2, Núm. 6, pp. e260-e266

2014

  1. Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion

    British Journal of Haematology, Vol. 166, Núm. 2, pp. 189-201

  2. Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: A subset analysis from the MDS-004 study

    European Journal of Haematology, Vol. 93, Núm. 5, pp. 429-438

  3. Results of allogeneic stem cell transplantation in the Spanish MDS registry: Prognostic factors for low risk patients

    Leukemia Research, Vol. 38, Núm. 10, pp. 1199-1206

2013

  1. Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome

    Journal of Clinical Oncology, Vol. 31, Núm. 7, pp. 916-922

  2. Diagnosis and treatment of primary myelodysplastic syndromes in adults: Recommendations from the European LeukemiaNet

    Blood, Vol. 122, Núm. 17, pp. 2943-2964

2012

  1. Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome

    Cancer, Vol. 118, Núm. 1, pp. 127-133

  2. Prognostic value of trisomy 8 as a single anomaly and the influence of additional cytogenetic aberrations in primary myelodysplastic syndromes

    British Journal of Haematology, Vol. 159, Núm. 3, pp. 311-321

  3. Simultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in peripheral blood adversely affects survival

    Annals of Hematology, Vol. 91, Núm. 12, pp. 1887-1895

  4. The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome

    Leukemia Research, Vol. 36, Núm. 3, pp. 287-292

2011

  1. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

    Blood, Vol. 118, Núm. 14, pp. 3765-3776

  2. Cytogenetic risk stratification in chronic myelomonocytic leukemia

    Haematologica, Vol. 96, Núm. 3, pp. 375-383

  3. Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome

    Cancer, Vol. 117, Núm. 24, pp. 5529-5537

2010

  1. Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements

    Annals of Hematology, Vol. 89, Núm. 2, pp. 147-154

2006

  1. Donor age and degree of HLA matching have a major impact on the outcome of unrelated donor haematopoietic cell transplantation for chronic myeloid leukaemia

    Bone Marrow Transplantation, Vol. 37, Núm. 1, pp. 33-40

2002

  1. Analysis of factors associated with low peripheral blood progenitor cell collection in normal donors.

    Transfusion, Vol. 42, Núm. 1, pp. 4-9

  2. Second mobilization and collection of peripheral blood progenitor cells in healthy donors is associated with lower CD34+ cell yields

    Journal of Hematotherapy and Stem Cell Research, Vol. 11, Núm. 4, pp. 705-709

1999

  1. Administration of recombinant human granulocyte colony-stimulating factor to normal donors: Results of the Spanish National Donor Registry

    Bone Marrow Transplantation, Vol. 24, Núm. 7, pp. 723-728